David Munn, M.D.
School of Medicine
|M.D.||Medical College of Georgia||Augusta, GA||1984|
|B.A.||Mercer University||Macon, GA||1978|
- Post-doctoral Experience
- Honors and Awards
- Research Interests
- Study of the regulation of T cell activation by antigen-presenting cells (macrophages and dendritic cells). A major focus of the laboratory is the immunoregulatory role of tryptophan metabolism via the enzyme indoleamine 2,3-dioxygenase (IDO) expressed by antigen-presenting cells. Active projects include: (1) the role of IDO-expressing dendritic cells in maintaining tolerance to self in the peripheral T cell compartment; (2) cell cycle regulation and anergy induction in T cells via IDO-induced activation of the GCN2-kinase pathway; (3) preclinical and clinical development of IDO inhibitor drugs for treatment of patients with cancer and HIV.
- Representative Publications
- Munn DH, Sharma MD, Baban B, Harding HP, Zhang Y, Ron D, Mellor AL. GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3 dioxygenase. Immunity 22:633-642 (2005)
Potula R, Poluektova L, Knipe B, Chrastil J, Heilman D, Dou H, Takikawa O, Munn DH, Gendelman HE PersidskyY. Inhibition of Indoleamine 2,3-dioxygenase (IDO) enhances elimination of virus infected macrophages in animal model of HIV-1 encephalitis. Blood 106:2382-2390 (2005)
Munn DH, Sharma MD, Hou D, Baban B, Lee JR, Antonia SJ, Messina JL, Chandler P, Koni PA, Mellor AL. Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. J Clin Invest 114:280-190 (2004)
Munn DH, Mellor AL. IDO and tolerance to tumors. Trends Molec Med 10:15-18 (2004)
Mellor AL, Munn, DH. Indoleamine 2,3-dioxygenase expression in dendritic cells: tolerance and tryptophan catabolism. Nature Rev Immunol 25:563-565 (2004)